The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
A NETRF-funded clinical trial looks at a cancer vaccine called SurVaxM in neuroendocrine cancer to help slow or stop the spread of neuroendocrine tumors.
Immunotherapy has been called one of the most significant advances in cancer in decades. While this approach may work in some cancers, it is unclear
He is a pioneer whose work has helped extend the horizon of cancer care, creating a new category of individualized immunotherapy. Carl June, MD, has conducted 25 years of scientific research to advance CAR T-cell therapy. And all that knowledge is now helping to tackle NETs.